COLR:EURONEXT BRUSSELSColruyt Group N.V. Analysis
Data as of 2026-05-23 - not real-time
€33.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Colruyt Group is trading well below its 20‑day (33.31) and 50‑day (33.77) moving averages, with the price at €33 sitting under a clear bearish trend. RSI is extremely low at 12.6, indicating the stock is deeply oversold, while the MACD shows a tiny bullish histogram suggesting a possible short‑term reversal. Volume has been decreasing, raising concerns about liquidity, and the 30‑day volatility of about 10.5% is moderate. On the fundamentals side, revenue is growing modestly (4.5%) but margins remain thin (gross 29%, operating 4%) and free cash flow is negative, though the company still delivers a generous 4.18% dividend yield. The DCF‑derived fair value of €49.8 is far above the current price, implying a sizable undervaluation despite cash‑flow headwinds.
Given the defensive grocery sector, very low beta, and strong dividend payout, the stock offers a value‑oriented play for investors willing to tolerate short‑term price weakness. However, the negative free cash flow and declining trading interest suggest caution until the price stabilises above the support around €32.9.
Given the defensive grocery sector, very low beta, and strong dividend payout, the stock offers a value‑oriented play for investors willing to tolerate short‑term price weakness. However, the negative free cash flow and declining trading interest suggest caution until the price stabilises above the support around €32.9.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering near technical support
- Extremely oversold RSI
- Decreasing volume and liquidity concerns
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF valuation gap indicating upside
- Attractive dividend yield in a defensive sector
- Potential rebound from oversold conditions
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Stable consumer‑defensive business model
- Low market beta reducing systematic risk
- Long‑term dividend income and possible cash‑flow improvement
Key Metrics & Analysis
Financial Health
Revenue Growth4.50%
Profit Margin2.62%
P/E Ratio13.4
ROE9.52%
ROA3.86%
Debt/Equity29.43
P/B Ratio1.3
Op. Cash Flow€597.9M
Free Cash Flow€-361962496
Technical Analysis
TrendBearish
RSI12.6
Support€32.87
Resistance€34.07
MA 20€33.31
MA 50€33.77
MA 200€35.73
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair Value€49.77
GradeUndervalued
TypeValue
Dividend Yield4.18%
Risk Assessment
Beta0.00
Volatility10.49%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.